53
Participants
Start Date
May 31, 2014
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
UCB4940 40 mg
"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
UCB4940 80 mg
"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
UCB4940 160 mg
"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
UCB4940 240 mg
"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
UCB4940 320 mg
"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
UCB4940 560 mg
"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
Placebo
"* Pharmaceutical Form: solution~* Concentration: 0.9 % sodium chloride~* Route of Administration: intravenous"
001, Sofia
002, Saint Chisinau
003, Manchester
Collaborators (3)
Parexel
INDUSTRY
MAC Clinical Research
OTHER
Comac Medical
INDUSTRY
ARENSIA, Moldova
UNKNOWN
UCB Celltech
INDUSTRY